Aditx Therapeutics(ADTX) - 2020 Q2 - Quarterly Report
Aditx Therapeutics(ADTX)2020-08-14 05:24
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 001-38561 Aditx Therapeutics, Inc. (Exact name of registrant as specified in its charter) | --- | -- ...